Evaluating the effectiveness and safety of AD-209 for hypertension
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
This study is testing a new medication called AD-209 to see if it can safely lower blood pressure in people with high blood pressure.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 280 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Addpharma Inc. Industry-sponsored |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06348576 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the efficacy and safety of a new medication, AD-209, in patients with essential hypertension. Participants will receive either AD-209, a related compound AD-2091, or a placebo to compare outcomes. The study will involve monitoring blood pressure levels and any side effects experienced by participants over the course of the trial. The goal is to determine if AD-209 can provide a safe and effective treatment option for managing hypertension.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with essential hypertension who can provide informed consent.
Not a fit: Patients with orthostatic hypotension or those experiencing related symptoms may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a new effective option for patients struggling with hypertension.
How similar studies have performed: While there have been various studies on hypertension treatments, the specific approach with AD-209 is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed informed consent * Other inclusions applied Exclusion Criteria: * Orthostatic hypotension with symptom * Other exclusions applied
Where this trial is running
Seoul
- Korea University Guro Hospital — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Chang Gyu Park, M.D., Ph.D — Korea University Guro Hospital
- Study coordinator: Kyung Tae Kim, D.V.M
- Email: ktkim@addpharma.co.kr
- Phone: 82-031-891-5661
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.